Marc Tischkowitz
Overview
Explore the profile of Marc Tischkowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
249
Citations
11612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Y, Allen I, Funingana G, Tischkowitz M, Joko-Fru Y
BJC Rep
. 2025 Mar;
3(1):14.
PMID: 40069561
Background: PARP inhibitors are effective in treating ovarian cancer, especially for BRCA1/2 pathogenic variant carriers and those with HRD (homologous recombination deficiency). Concerns over toxicity and costs have led to...
2.
Hassan H, Rahman T, Bacon A, Knott C, Allen I, Huntley C, et al.
BMJ Oncol
. 2025 Mar;
4(1):e000574.
PMID: 40046828
Objectives: To investigate the association between bilateral salpingo-oophorectomy (BSO) and long-term health outcomes in women with a personal history of breast cancer. Methods And Analysis: We used data on women...
3.
Dhawan A, Baitamouni S, Liu D, Yehia L, Anthony K, McCarther A, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39937242
Purpose: PTEN hamartoma tumour syndrome (PHTS) is an autosomal dominant cancer-predisposition and overgrowth syndrome occurring due to pathogenic germline variants in the PTEN gene, with an increased risk of both...
4.
Breast Cancer Susceptibility Gene Sequence Variations and Development of Contralateral Breast Cancer
Reiner A, Watt G, Malone K, Lynch C, John E, Knight J, et al.
JAMA Netw Open
. 2025 Jan;
7(12):e2452158.
PMID: 39786405
Importance: Heterogeneity in development of estrogen receptor (ER)-specific first primary breast cancer exists due to deleterious germline variants in moderate- to high-penetrance breast cancer susceptibility genes, but it is unknown...
5.
Mavaddat N, Ficorella L, Carver T, Lee A, Cunningham A, Lush M, et al.
Cancer Epidemiol Biomarkers Prev
. 2025 Jan;
34(1):205.
PMID: 39780621
No abstract available.
6.
Pal T, Schon K, Astiazaran-Symonds E, Balmana J, Foulkes W, James P, et al.
Genet Med
. 2024 Dec;
27(1):101243.
PMID: 39636577
Purpose: ATM germline pathogenic variants (GPVs) are associated with a moderately increased risk of female breast cancer, pancreatic cancer, and prostate cancer. Resources for managing ATM heterozygotes in clinical practice...
7.
Li S, Madanat-Harjuoja L, Leslie G, Barnes D, Bolla M, Dennis J, et al.
J Natl Cancer Inst
. 2024 Nov;
PMID: 39585318
Background: Whether carriers of BRCA1 or BRCA2 (BRCA1/2) pathogenic variants (PVs) have increased risks of childhood, adolescent, and young adult (CAYA) cancers is controversial. We aimed to evaluate this risk...
8.
9.
Usher-Smith J, Tooth G, Follows A, Badran A, Youngs A, Forman A, et al.
BJC Rep
. 2024 Nov;
2(1):2.
PMID: 39516250
Background: The National Institute for Health and Care Excellence (NICE) recommends that women in England at above-population risk be offered additional breast screening and, depending on the level of risk,...
10.